John W. Kozarich's SEC Form 4 activity over the past five months reveals a consistent, one-directional pattern: he has been a steady seller of Ligand Pharmaceuticals (LGND) shares, with no open-market purchases recorded. Across 53 total filings, all involving LGND, his cumulative sales reached approximately $1.43 million, while his acquisition value stood at zero. The recent window, spanning February through May 2026, shows 21 sell transactions, with the largest single sale occurring on May 13, 2026, at $352,012.50. Smaller sales, ranging from roughly $192 to $102,816, were clustered on monthly dates—February 2, March 2, April 1, and May 1—suggesting a routine, scheduled disposition of shares.
The transaction codes provide important context for interpreting the selling bias. Several of the sales were paired with "M" codes, indicating option exercises on the same dates—for example, on May 12 and May 13, 2026, Kozarich exercised options valued at $31,905.09 and $109,478.25, respectively, immediately preceding sales of $102,816 and $352,012.50. This exercise-and-sell pattern is typical of a liquidity event rather than a discretionary market bet. Additionally, two "A" grants on June 5, 2026, with zero dollar value, represent compensation awards, not purchases, and do not offset the selling trend.
The absence of any "P" (open-market purchase) codes across the entire filing history underscores that Kozarich has not added to his position on the open market. Instead, his activity is dominated by "S" sales, which totaled over $1.4 million, alongside mechanical "M" exercises and "A" grants. The data points to a net disposition of LGND stock over the period, with the selling bias clear in both the frequency and dollar volume of transactions. While the monthly cadence and option-exercise pairings suggest a structured approach, the overall direction is unambiguous: Kozarich has been reducing his stake in Ligand Pharmaceuticals, with no recent buying activity to counterbalance the outflow.
AI-assisted summary